This one could get messy, Fools. At least both sides of this impending pharmaceutical battle have a drug designed to stop bleeding.
Thrombin-JMI is used to stop bleeding during surgeries. The protein product is isolated from cows, which can trigger antibody production in patients if their immune system recognizes the protein as foreign. Those antibodies could interfere with the coagulation process, leading to complications. ZymoGenetic's competing blood-clotting drug, Recothrom, is a human protein manufactured in a plant, so it generally doesn't have that issue.
King's product had sales of $96 million in the first half of the year, while Recothrom sales were a paltry $10.5 million. Johnson & Johnson
If ZymoGenetics' drug is so much safer, why hasn't Recothrom become the king of the operating room? Because "safer" is relative.
ZymoGenetics says that it has found more than 25 published cases of antibodies causing issues with coagulation since 2000. That's really not very many, and while some would argue that one is too many, based on sales, it seems that doctors aren't that worried about it. I doubt the FDA will be, either.
ZymoGenetics was up nearly 7% on the news yesterday, and it has climbed higher today, but Fools should be careful here. Recothrom is ZymoGenetics' only product, but it'll never be a blockbuster, even if the FDA fulfills ZymoGenetics' wildest fantasies.
The company's future -- and therefore its stock price -- lie in the success or failure of its pipeline, including finding a partner for Interleukin-21, which has shown decent results when combined with Bayer's and Onyx Pharmaceuticals'
Looking to score big from new technology? It only takes three years.
Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. Johnson & Johnson is a selection of the Income Investor newsletter. The Fool has a disclosure policy.